April 18 - 22, 2015
Pennsylvania Convention Center
The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak. Eight outstanding NextGen Stars will present their work in major sessions at the AACR Annual Meeting 2015. Selections were made through a competitive application process that was limited to AACR Associate Members and AACR Active Members who were at the junior faculty level (not higher than assistant professor or equivalent).
Congratulations to the 2015 NextGen Stars!
Christopher E. Barbieri, Weill Cornell Medical College of Cornell University, New York, New York
SPOP mutation is associated with genomic instability in prostate cancerRecent Advances in Diagnostics and Therapeutics ResearchExploiting DNA Repair Deficiencies in CancerMonday, April 20, 2015, 10:30 a.m.-12:30 p.m.
Room 113, Pennsylvania Convention Center
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MassachusettsClinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterationsMajor SymposiumMechanisms of Resistance: From Signaling Pathways to Stem CellsTuesday, April 21, 2015, 10 a.m. - 12 p.m.Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Courtney Hodges, Howard Hughes Medical Institute and Stanford University School of Medicine, Stanford, CaliforniaChromatin accessibility underlies the tumor-suppression role of BAF (mSWI/SNF) complexes in many malignanciesRecent Advances in Diagnostics and Therapeutics ResearchDNA Repair Pathways in Cancer: Basic Biology and Clinical UtilityTuesday, April 21, 2015, 1 - 3 p.m.Room 121, Pennsylvania Convention Center
Hongbo Pang, Sanford-Burnham Medical Research Institute, La Jolla, CaliforniaA novel endocytic and intercellular transport pathway for drug delivery across blood vessels and into nutrient-deprived tumor cellsRecent Advances in Diagnostics and Therapeutics ResearchNovel Delivery Systems and/or Formulations in Cancer TreatmentMonday, April 20, 2015, 1 - 3 p.m.Room 126, Pennsylvania Convention CenterRushika M. Perera, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston,
MassachusettsTranscriptional mechanisms for autophagy regulation and metabolic reprogramming in pancreatic cancerRecent Advances in Organ Site ResearchPancreatic Cancer in 2015: An Integrated View of a Complex DiseaseWednesday, April 22, 2015, 10 a.m. - 12 p.m.Room 118, Pennsylvania Convention Center
Catherine C. Smith, University of California, San Francisco, CaliforniaPolyclonal and heterogeneous resistance to targeted therapy in leukemiaMajor SymposiumTargeted Therapies in Hematologic MalignanciesMonday, April 20, 2015, 10:30 a.m. -12:30 p.m.Room 201, Pennsylvania Convention Center
Surojit Sur, Ludwig Center at the Johns Hopkins Kimmel Cancer Center, Baltimore, MarylandThe Trojan Horse Strategy: Packaging chemotherapeutics can help alleviate toxicityMajor SymposiumApplying Systems Biology in the Oncology ClinicTuesday, Apr 21, 2015, 1 - 3 p.m.Room 118, Pennsylvania Convention Center
View the webcasts of the NextGen Stars' presentations from the AACR Annual Meeting 2014:
Andrea Bertotti, University of Turin, Turin, ItalyRational drug combinations to improve anti-EGFR targeted therapies in metastatic colorectal cancerPresented in a Current Concepts session on Novel Approaches for Understanding the Biology of Colorectal Cancer
Priscilla K. Brastianos, Massachusetts General Hospital, Boston, Massachusetts
Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (audio only)Presented in a Major Symposium on Novel Mechanisms of Metastasis
Brooke M. Emerling, Weill Cornell Medical College, New York, New YorkDepletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53 null tumorsPresented in a Major Symposium on Synthetic Lethality
Maurizio Scaltriti, Memorial Sloan Kettering Cancer Center, New York, New YorkBlockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancerPresented in a Current Concepts session on Breast Cancer: Progress in Basic and Translational Research
David T. Ting, Massachusetts General Hospital, Charlestown, Massachusetts
Diversity of circulating tumor cells in a mouse pancreatic cancer model identified by single cell RNA sequencingPresented in a Current Concepts session on Single Cell Analysis of the Tumor
Top of page